These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 15776380)

  • 1. HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach.
    Harrigan PR; Wynhoven B; Brumme ZL; Brumme CJ; Sattha B; Major JC; de la Rosa R; Montaner JS
    J Infect Dis; 2005 Apr; 191(8):1325-30. PubMed ID: 15776380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naïve patients in Slovenia, 2000-2004.
    Babic DZ; Zelnikar M; Seme K; Vandamme AM; Snoeck J; Tomazic J; Vidmar L; Karner P; Poljak M
    Virus Res; 2006 Jun; 118(1-2):156-63. PubMed ID: 16417938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study.
    Di Giambenedetto S; Bracciale L; Colafigli M; Cattani P; Pinnetti C; Bacarelli A; Prosperi M; Fadda G; Cauda R; De Luca A
    Antivir Ther; 2007; 12(5):835-9. PubMed ID: 17713168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure.
    Lohse N; Jørgensen LB; Kronborg G; Møller A; Kvinesdal B; Sørensen HT; Obel N; Gerstoft J;
    Antivir Ther; 2007; 12(6):909-17. PubMed ID: 17926645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.
    Escoto-Delgadillo M; Vázquez-Valls E; Ramírez-Rodríguez M; Corona-Nakamura A; Amaya-Tapia G; Quintero-Pérez N; Panduro-Cerda A; Torres-Mendoza BM
    HIV Med; 2005 Nov; 6(6):403-9. PubMed ID: 16268822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance of genotypic resistance mutations in chronic HIV-1 treated individuals after completion of the National Access to Antiretroviral Program in Thailand.
    Sukasem C; Churdboonchart V; Chasombat S; Kohreanudom S; Watitpun C; Pasomsub E; Piroj W; Tiensuwan M; Chantratita W
    Infection; 2007 Apr; 35(2):81-8. PubMed ID: 17401711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.
    Spacek LA; Shihab HM; Kamya MR; Mwesigire D; Ronald A; Mayanja H; Moore RD; Bates M; Quinn TC
    Clin Infect Dis; 2006 Jan; 42(2):252-9. PubMed ID: 16355337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
    Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
    Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients.
    Parisi SG; Boldrin C; Cruciani M; Nicolini G; Cerbaro I; Manfrin V; Dal Bello F; Franchin E; Franzetti M; Rossi MC; Cattelan AM; Romano L; Zazzi M; Andreoni M; Palù G
    J Clin Microbiol; 2007 Jun; 45(6):1783-8. PubMed ID: 17442799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?
    Simcock M; Sendi P; Ledergerber B; Keller T; Schüpbach J; Battegay M; Günthard HF;
    Antivir Ther; 2006; 11(3):305-14. PubMed ID: 16759046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral drug resistance and resistance testing.
    Gallant JE
    Top HIV Med; 2005 Dec-2006 Jan; 13(5):138-42. PubMed ID: 16377851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children.
    Delaugerre C; Warszawski J; Chaix ML; Veber F; Macassa E; Buseyne F; Rouzioux C; Blanche S
    J Med Virol; 2007 Sep; 79(9):1261-9. PubMed ID: 17607781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotypic resistance mutations in treatment-naïve and treatment-experienced patients under widespread use of antiretroviral drugs in Thailand: implications for further epidemiologic surveillance.
    Sukasem C; Churdboonchart V; Sirisidthi K; Riengrojpitak S; Chasombat S; Watitpun C; Piroj W; Tiensuwan M; Chantratita W
    Jpn J Infect Dis; 2007 Sep; 60(5):284-9. PubMed ID: 17881868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
    Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.
    Valer L; de Mendoza C; Soriano V
    J Med Virol; 2005 Dec; 77(4):460-4. PubMed ID: 16254964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prevalence of antiretroviral drug genotypic resistance among HIV patients in Cuenca, Spain].
    Rodriguez-Escudero MJ; Prada de Medio E; Rosa Herranz C; Martinez Medina MC; Franquelo Gutierrez R
    Rev Esp Quimioter; 2007 Jun; 20(2):203-5. PubMed ID: 17893756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
    Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
    Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the diversity of the HIV-1 pol gene and drug resistance associated changes among drug-naïve patients in Burkina Faso.
    Tebit DM; Sangaré L; Tiba F; Saydou Y; Makamtse A; Somlare H; Bado G; Kouldiaty BG; Zabsonre I; Yameogo SL; Sathiandee K; Drabo JY; Kräusslich HG
    J Med Virol; 2009 Oct; 81(10):1691-701. PubMed ID: 19697403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.